Early detection with blood instead of cerebrospinal fluid
Alzheimer's disease often begins insidiously. One of its hallmarks is the hyperphosphorylation of tau proteins, which are deposited in the fibers of nerve cells and damage them. In everyday life, the gradual deterioration of nerve cells and contacts is easy to overlook. This makes it all the more important to make a rapid, reliable diagnosis once the first warning signs appear.
In the past, a time-consuming examination of the cerebrospinal fluid was usually necessary, but today we can reach our goal more easily with new methods. Blood tests and the innovative biomarker phospho-Tau217 (pTau217) provide fast and reliable comparable results.
phosopho-Tau217 (pTau217) makes diagnosis easier
With pTau217, we have a particularly promising marker. As soon as the first cognitive impairments appear, we can now make precise assessments by analyzing pTau217 in the blood. In doing so, we achieve a high level of agreement with imaging procedures. As the test is carried out in blood and not in cerebrospinal fluid, the procedure is much more convenient for patients.
As a doctor, this gives you the opportunity to detect Alzheimer's disease at an early stage and to assess its further progression more accurately. Patients' performance can be maintained for longer thanks to timely treatment. The pTau217 biomarker offers clear advantages, particularly with regard to new therapeutic approaches.